{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:29:58Z","timestamp":1788974998700,"version":"build-2803163510"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","award":["GR-2019-12370435"],"award-info":[{"award-number":["GR-2019-12370435"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Epitech Group"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Frontotemporal dementia is a devastating neurodegenerative disorder for which no pharmacological treatments have been approved. Neuroinflammation plays a central role in driving the pathogenic mechanisms underlying frontotemporal dementia. In the last few years, co-ultramicronized palmitoylethanolamide combined with luteoline has emerged as a potential therapeutic molecule in neurodegenerative disorders pathogenically related to frontotemporal dementia, for its demonstrated strong anti-inflammatory and neuroprotective properties. Here we wanted to determine whether treatment with co-ultramicronized palmitoylethanolamide combined with luteoline may have a clinical impact in frontotemporal dementia patients. We performed a Phase 2, monocentric, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of co-ultramicronized palmitoylethanolamide combined with luteoline in frontotemporal dementia patients. Forty eight patients with a diagnosis of probable frontotemporal dementia were randomly assign in a 1:1 ratio to receive co-ultramicronized palmitoylethanolamide combined with luteoline oral suspension at the dosage of 700\u2005mg + 70\u2005mg twice\/day (n = 25) or placebo twice\/day (n = 23) for 24 weeks. The primary efficacy outcome measure was the change at 24-weeks in the Clinical Dementia Rating Dementia Staging Instrument from the National Alzheimer\u2019s Coordinating Center and frontotemporal lobar degeneration modules\u2014sum of boxes (CDR plus NACC FTLD\u2014SoB). Secondary outcome measures included the Frontal Assessment Battery, Screening for Aphasia in Neurodegeneration, Alzheimer\u2019s Disease Cooperative Study\u2014Activities of Daily Living, Neuropsychiatric Inventory, Mini-Mental State Examination and Addenbrooke\u2019s Cognitive Examination Revised. Among 48 patients randomized [mean (SD) age 63.2 (8.4), 23 (47.9%) female], 45 (93%) completed the study. Patients in the co-ultramicronized palmitoylethanolamide combined with luteoline group showed less decline for the primary outcome measure (CDR plus NACC FTLD) as compared with patients treated with placebo. The estimated mean change (W0\u2013W24) in CDR plus NACC FTLD score was 0.53 for the co-ultramicronized palmitoylethanolamide combined with luteoline group [95% confidence interval (0.12\u20130.94)] and 1.39 for the placebo group [95% confidence interval (0.96\u20131.82)], with an estimated mean difference between of 0.86 [95% confidence interval (0.28\u20131.45), P = 0.005]. Estimated mean change in Alzheimer\u2019s Disease Cooperative Study\u2014Activities of Daily Living score was \u22121.8 for co-ultramicronized palmitoylethanolamide combined with luteoline (95% confidence interval, \u22123.67 to 0.06) and \u22127.39 for placebo (95% confidence interval \u22129.34 to \u22125.45). Estimated mean change in screening for Aphasia in neurodegeneration scores was \u22123.987 for co-ultramicronized palmitoylethanolamide combined with luteoline (95% confidence interval, \u22127.75 to \u22120.22) and \u221210.35 for placebo (95% confidence interval, \u221214.33 to \u22126.37). No effect of treatment was found on other secondary outcome measures. Our results demonstrate that co-ultramicronized palmitoylethanolamide combined with luteoline shows promising efficacy in slowing down the progression of cognitive and functional symptoms in frontotemporal dementia patients. These findings warrant further investigation and offer potential for the development of effective therapeutic strategies for frontotemporal dementia.<\/jats:p>","DOI":"10.1093\/braincomms\/fcaf080","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T15:17:06Z","timestamp":1741187826000},"source":"Crossref","is-referenced-by-count":7,"title":["Phase 2 study of palmitoylethanolamide combined with luteoline in frontotemporal dementia patients"],"prefix":"10.1093","volume":"7","author":[{"given":"Martina","family":"Assogna","sequence":"first","affiliation":[{"name":"Department of Clinical and Behavioural Neurology, Santa Lucia Foundation IRCCS , Rome 00179 ,","place":["Italy"]},{"name":"Department of Neurosciences, S. Camillo-Forlanini Hospital , Rome 00152 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Lorenzo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Behavioural Neurology, Santa Lucia Foundation IRCCS , Rome 00179 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Bonn\u00ec","sequence":"additional","affiliation":[{"name":"Department of Clinical and Behavioural Neurology, Santa Lucia Foundation IRCCS , Rome 00179 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Borghi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Behavioural Neurology, Santa Lucia Foundation IRCCS , Rome 00179 ,","place":["Italy"]},{"name":"Department of Neuroscience and Rehabilitation, University of Ferrara, and Center for Translational Neurophysiology of Speech and Communication (CTNSC), Italian Institute of Technology (IIT) , Ferrara 44121 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Cerulli Irelli","sequence":"additional","affiliation":[{"name":"Department of Human Neurosciences, Sapienza, University of Rome , Rome 00185 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Mencarelli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Behavioural Neurology, Santa Lucia Foundation IRCCS , Rome 00179 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Maiella","sequence":"additional","affiliation":[{"name":"Department of Clinical and Behavioural Neurology, Santa Lucia Foundation IRCCS , Rome 00179 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Minei","sequence":"additional","affiliation":[{"name":"Department of Clinical and Behavioural Neurology, Santa Lucia Foundation IRCCS , Rome 00179 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Esposito","sequence":"additional","affiliation":[{"name":"Department of Clinical and Behavioural Neurology, Santa Lucia Foundation IRCCS , Rome 00179 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias P","family":"Casula","sequence":"additional","affiliation":[{"name":"Department of Clinical and Behavioural Neurology, Santa Lucia Foundation IRCCS , Rome 00179 ,","place":["Italy"]},{"name":"Department of Systems Medicine, University of Tor Vergata , Rome 00133 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Pezzopane","sequence":"additional","affiliation":[{"name":"Department of Clinical and Behavioural Neurology, Santa Lucia Foundation IRCCS , Rome 00179 ,","place":["Italy"]},{"name":"Department of Neuroscience and Rehabilitation, University of Ferrara, and Center for Translational Neurophysiology of Speech and Communication (CTNSC), Italian Institute of Technology (IIT) , Ferrara 44121 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"D\u2019Acunto","sequence":"additional","affiliation":[{"name":"Department of Clinical and Behavioural Neurology, Santa Lucia Foundation IRCCS , Rome 00179 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Porrazzini","sequence":"additional","affiliation":[{"name":"Department of Clinical and Behavioural Neurology, Santa Lucia Foundation IRCCS , Rome 00179 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Candeo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Behavioural Neurology, Santa Lucia Foundation IRCCS , Rome 00179 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Ferraresi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Behavioural Neurology, Santa Lucia Foundation IRCCS , Rome 00179 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Motta","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Tor Vergata , Rome 00133 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Office of Research and Clinical Trials, Fondazione Poliambulanza Istituto Ospedaliero , Brescia 25124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Caltagirone","sequence":"additional","affiliation":[{"name":"Department of Clinical and Behavioural Neurology, Santa Lucia Foundation IRCCS , Rome 00179 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Martorana","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Tor Vergata , Rome 00133 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6155-9439","authenticated-orcid":false,"given":"Giacomo","family":"Koch","sequence":"additional","affiliation":[{"name":"Department of Clinical and Behavioural Neurology, Santa Lucia Foundation IRCCS , Rome 00179 ,","place":["Italy"]},{"name":"Department of Neuroscience and Rehabilitation, University of Ferrara, and Center for Translational Neurophysiology of Speech and Communication (CTNSC), Italian Institute of Technology (IIT) , Ferrara 44121 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"issue":"S5","key":"2025032523015449100_fcaf080-B1","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1002\/ana.10572","article-title":"Epidemiology and genetics of frontotemporal dementia\/Pick\u2019s disease","volume":"54","author":"Bird","year":"2003","journal-title":"Ann Neurol"},{"issue":"8","key":"2025032523015449100_fcaf080-B2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrneurol.2012.117","article-title":"Advances in understanding the molecular basis of frontotemporal dementia","volume":"8","author":"Rademakers","year":"2012","journal-title":"Nat Rev Neurol"},{"issue":"Pt 9","key":"2025032523015449100_fcaf080-B3","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia","volume":"134","author":"Rascovsky","year":"2011","journal-title":"Brain"},{"issue":"11","key":"2025032523015449100_fcaf080-B4","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","article-title":"Classification of primary progressive aphasia and its variants","volume":"76","author":"Gorno-Tempini","year":"2011","journal-title":"Neurology"},{"key":"2025032523015449100_fcaf080-B5","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1212\/WNL.51.6.1546","article-title":"Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria","volume":"51","author":"Neary","year":"1998","journal-title":"Neurology"},{"issue":"2","key":"2025032523015449100_fcaf080-B6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3109\/09540261.2013.776523","article-title":"The epidemiology of frontotemporal dementia","volume":"25","author":"Onyike","year":"2013","journal-title":"Int Rev Psychiatry"},{"issue":"11","key":"2025032523015449100_fcaf080-B7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11940-014-0319-0","article-title":"Treatment of frontotemporal dementia","volume":"16","author":"Tsai","year":"2014","journal-title":"Curr Treat Options Neurol"},{"issue":"2","key":"2025032523015449100_fcaf080-B8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.psc.2020.02.006","article-title":"Frontotemporal dementia","volume":"43","author":"Younes","year":"2020","journal-title":"Psychiatr Clin North Am"},{"issue":"3","key":"2025032523015449100_fcaf080-B9","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/brain\/awaa033","article-title":"Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum","volume":"143","author":"Bevan-Jones","year":"2020","journal-title":"Brain"},{"issue":"8","key":"2025032523015449100_fcaf080-B10","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1093\/brain\/awad078","article-title":"Microglial activation in the frontal cortex predicts cognitive decline in frontotemporal dementia","volume":"146","author":"Malpetti","year":"2023","journal-title":"Brain"},{"issue":"9","key":"2025032523015449100_fcaf080-B11","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41582-019-0231-z","article-title":"Neuroinflammation in frontotemporal dementia","volume":"15","author":"Bright","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"2025032523015449100_fcaf080-B12","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41380-021-01384-8","article-title":"Deficient neurotransmitter systems and synaptic function in frontotemporal lobar degeneration\u2014Insights into disease mechanisms and current therapeutic approaches","volume":"27","author":"Huber","year":"2022","journal-title":"Mol Psychiatry"},{"issue":"14","key":"2025032523015449100_fcaf080-B13","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.neuron.2021.05.020","article-title":"C9orf72 deficiency promotes microglial-mediated synaptic loss in aging and amyloid accumulation","volume":"109","author":"Lall","year":"2021","journal-title":"Neuron"},{"issue":"8","key":"2025032523015449100_fcaf080-B14","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3390\/biom12081161","article-title":"Synaptic effects of palmitoylethanolamide in neurodegenerative disorders","volume":"12","author":"Assogna","year":"2022","journal-title":"Biomolecules"},{"issue":"11","key":"2025032523015449100_fcaf080-B15","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1073\/pnas.1600251113","article-title":"Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy","volume":"113","author":"Palma","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2025032523015449100_fcaf080-B16","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0000000000004232","article-title":"Transcranial magnetic stimulation distinguishes Alzheimer disease from frontotemporal dementia","volume":"89","author":"Benussi","year":"2017","journal-title":"Neurology"},{"issue":"5","key":"2025032523015449100_fcaf080-B17","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/brain\/awx327","article-title":"Neurotransmitter deficits from frontotemporal lobar degeneration","volume":"141","author":"Murley","year":"2018","journal-title":"Brain"},{"issue":"4","key":"2025032523015449100_fcaf080-B18","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3233\/JAD-200426","article-title":"Effects of palmitoylethanolamide combined with luteoline on frontal lobe functions, high frequency oscillations, and GABAergic transmission in patients with frontotemporal dementia","volume":"76","author":"Assogna","year":"2020","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"2025032523015449100_fcaf080-B19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/alz.12033","article-title":"Utility of the global CDR\u00ae plus NACC FTLD rating and development of scoring rules: Data from the ARTFL\/LEFFTDS consortium","volume":"16","author":"Miyagawa","year":"2020","journal-title":"Alzheimers Dement"},{"issue":"2","key":"2025032523015449100_fcaf080-B20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/brain\/awy319","article-title":"Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials","volume":"142","author":"Staffaroni","year":"2019","journal-title":"Brain"},{"issue":"4","key":"2025032523015449100_fcaf080-B21","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/jnnp-2018-318603","article-title":"Therapeutic trial design for frontotemporal dementia and related disorders","volume":"90","author":"Desmarais","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"2025032523015449100_fcaf080-B22","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1212\/WNL.55.11.1621","article-title":"The FAB: A Frontal Assessment Battery at bedside","volume":"55","author":"Dubois","year":"2000","journal-title":"Neurology"},{"issue":"2","key":"2025032523015449100_fcaf080-B23","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s10072-005-0443-4","article-title":"The Frontal Assessment Battery (FAB): Normative values in an Italian population sample","volume":"26","author":"Appollonio","year":"2005","journal-title":"Neurol Sci"},{"issue":"8","key":"2025032523015449100_fcaf080-B24","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s10072-017-3001-y","article-title":"SAND: A screening for Aphasia in NeuroDegeneration. Development and normative data","volume":"38","author":"Catrical\u00e0","year":"2017","journal-title":"Neurol Sci"},{"issue":"Suppl. 2","key":"2025032523015449100_fcaf080-B25","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer\u2019s disease","volume":"11","author":"Galasko","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"5 Suppl 6","key":"2025032523015449100_fcaf080-B26","first-page":"S10\u2013","article-title":"The neuropsychiatric inventory: Assessing psychopathology in dementia patients","volume":"48","author":"Cummings","year":"1997","journal-title":"Neurology"},{"issue":"3","key":"2025032523015449100_fcaf080-B27","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1468-1331.1996.tb00423.x","article-title":"Mini-mental state examination: A normative study in Italian elderly population","volume":"3","author":"Magni","year":"1996","journal-title":"Eur J Neurol"},{"issue":"3","key":"2025032523015449100_fcaf080-B28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10072-015-2410-z","article-title":"The Addenbrooke\u2019s cognitive examination revised (ACE-R) and its sub-scores: Normative values in an Italian population sample","volume":"37","author":"Siciliano","year":"2016","journal-title":"Neurol Sci"},{"issue":"2","key":"2025032523015449100_fcaf080-B29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s10072-007-0791-3","article-title":"The frontal behavioural inventory (Italian version) differentiates frontotemporal lobar degeneration variants from Alzheimer\u2019s disease","volume":"28","author":"Alberici","year":"2007","journal-title":"Neurol Sci"},{"issue":"1","key":"2025032523015449100_fcaf080-B30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jalz.2019.06.4956","article-title":"New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures","volume":"16","author":"Boxer","year":"2020","journal-title":"Alzheimers Dement"},{"issue":"9","key":"2025032523015449100_fcaf080-B31","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/gps.4556","article-title":"Detecting clinical change with the CDR-FTLD: Differences between FTLD and AD dementia","volume":"32","author":"Mioshi","year":"2017","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3","key":"2025032523015449100_fcaf080-B32","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/01.wnl.0000171343.43314.6e","article-title":"Rate of progression differs in frontotemporal dementia and Alzheimer disease","volume":"65","author":"Rascovsky","year":"2005","journal-title":"Neurology"},{"issue":"1","key":"2025032523015449100_fcaf080-B33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13195-020-00753-9","article-title":"Characteristics and progression of patients with frontotemporal dementia in a regional memory clinic network","volume":"13","author":"Leroy","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"2025032523015449100_fcaf080-B34","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1212\/01.wnl.0000173837.82820.9f","article-title":"Frontotemporal dementia progresses to death faster than Alzheimer disease","volume":"65","author":"Roberson","year":"2005","journal-title":"Neurology"},{"issue":"3","key":"2025032523015449100_fcaf080-B35","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3390\/antiox9030216","article-title":"An update of palmitoylethanolamide and luteolin effects in preclinical and clinical studies of neuroinflammatory events","volume":"9","author":"Cordaro","year":"2020","journal-title":"Antioxidants (Basel)"},{"key":"2025032523015449100_fcaf080-B36","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3389\/fphar.2019.00821","article-title":"Palmitoylethanolamide (PEA) as a potential therapeutic agent in Alzheimer\u2019s disease","volume":"10","author":"Beggiato","year":"2019","journal-title":"Front Pharmacol"},{"key":"2025032523015449100_fcaf080-B37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.clinph.2022.10.017","article-title":"Co-ultramicronized palmitoylethanolamide\/luteolin normalizes GABAB-ergic activity and cortical plasticity in long COVID-19 syndrome","volume":"145","author":"Versace","year":"2023","journal-title":"Clin Neurophysiol"},{"issue":"1","key":"2025032523015449100_fcaf080-B38","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1038\/s41598-017-07519-8","article-title":"A novel crosstalk within the endocannabinoid system controls GABA transmission in the striatum","volume":"7","author":"Musella","year":"2017","journal-title":"Sci Rep"},{"key":"2025032523015449100_fcaf080-B39","doi-asserted-by":"crossref","first-page":"e37703","DOI":"10.7554\/eLife.37703","article-title":"Trpv1 receptor activation rescues neuronal function and network gamma oscillations from A\u03b2-induced impairment in mouse hippocampus in vitro","volume":"7","author":"Balleza-Tapia","year":"2018","journal-title":"Elife"},{"issue":"8","key":"2025032523015449100_fcaf080-B40","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1093\/brain\/awy176","article-title":"Reorganization of cortical oscillatory dynamics underlying disinhibition in frontotemporal dementia","volume":"141","author":"Hughes","year":"2018","journal-title":"Brain"},{"issue":"3","key":"2025032523015449100_fcaf080-B41","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.3390\/ijms16035555","article-title":"Palmitoylethanolamide inhibits glutamate release in rat cerebrocortical nerve terminals","volume":"16","author":"Lin","year":"2015","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2025032523015449100_fcaf080-B42","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ana.24731","article-title":"Impaired long-term potentiation-like cortical plasticity in presymptomatic genetic frontotemporal dementia","volume":"80","author":"Benussi","year":"2016","journal-title":"Ann Neurol"},{"key":"2025032523015449100_fcaf080-B43","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fnins.2019.00304","article-title":"Toward a glutamate hypothesis of frontotemporal dementia","volume":"13","author":"Benussi","year":"2019","journal-title":"Front Neurosci"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/7\/2\/fcaf080\/62276060\/fcaf080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/7\/2\/fcaf080\/62276060\/fcaf080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T07:52:16Z","timestamp":1743234736000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcaf080\/8052642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcaf080","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"fcaf080"}}